Blog

  • Common medications may secretly rewire your gut for years

    Common medications may secretly rewire your gut for years

    Medications a person took years ago can still influence the community of microbes living in their gut, according to a large study conducted by the University of Tartu Institute of Genomics.

    By examining stool samples and prescription data from…

    Continue Reading

  • New Global Standard for Hotel Excellence | Michelin – Groupe Michelin

    1. New Global Standard for Hotel Excellence | Michelin  Groupe Michelin
    2. 7 hotels in Singapore make it to inaugural global Michelin Keys selection, Raffles Hotel Singapore earns 3 keys  CNA Lifestyle
    3. Luxury Big Sur resort could win inaugural Michelin…

    Continue Reading

  • Gender-Specific Next-Generation Sequencing Reveals First Allelic Varia

    Gender-Specific Next-Generation Sequencing Reveals First Allelic Varia

    Introduction

    Alzheimer’s disease (AD) represents the most common form of dementia, afflicting over 50 million people worldwide, with numbers projected to triple by 2050.1 Notably, epidemiological studies consistently demonstrate significant…

    Continue Reading

  • SHIMANO launches a special edition in polished aluminum of its 10-speed CUES components

    SHIMANO launches a special edition in polished aluminum of its 10-speed CUES components

    SHIMANO has presented a new and striking version of its CUES components. A special edition in polished aluminum that combines modern performance with the elegance of classic finishes. With this release, the Japanese firm…

    Continue Reading

  • Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025

    – Dr Paul Brennan to present on the association of early biomarker modulation with long term clinical outcomes from the MATCH Ph II study of non-engineered macrophages in cirrhosis
    – Dr Lara Campana to present on anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapy in models of liver fibrosis

    EDINBURGH, Scotland and LONDON, Oct. 9, 2025 /PRNewswire/ — Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy in inflammatory and fibrotic diseases, today announces two abstracts have been selected for presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025. The conference will take place in Washington D.C., between 7-11 November 2025.

    Dr Paul Brennan MD, PhD, Clinical Lecturer in Hepatology, University of Dundee, UK, will present data from the University of Edinburgh’s MATCH 2 clinical trial demonstrating that regenerative macrophage therapy (RMT) is associated with early changes in biomarkers associated with liver function (INR; dMELD), which in turn correlate with much longer survival in patients with advanced cirrhosis. Details below:

    Title: Early modulation of INR and MELD after regenerative macrophage therapy is associated with favourable clinical outcomes at three-year follow-up

    Publication Number: 2435 

    Author: Dr. Paul Brennan, PhD

    Date/Time: 8 November 2025, 8:00am – 5:00pm EST

    Track: Portal Hypertension and Other Complications of Cirrhosis (“2280-2479”)

    Dr. Lara Campana, Ph.D., co-founder and Senior Vice President of Research and Translational Science at Resolution will present a poster detailing the preclinical data supporting the anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapies in models of liver fibrosis. Details below:

    Title: Assessment of regenerative macrophage therapy pharmacology supports anti-inflammatory and anti-fibrotic effects in preclinical models of liver fibrosis

    Publication Number: 3391

    Author: Dr Lara Campana, PhD

    Date/Time: 9 November 2025, 5:00pm – 6:30pm EST

    Track: Liver Fibrogenesis and Non-Parenchymal Cell Biology (“3335-3420”)

    Members of the Resolution senior leadership team will be attending the conference. Please reach out to set up a meeting to learn more about the Company.

    NOTES TO EDITORS

    About Resolution Therapeutics

    Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. The Company leverages its proprietary platform to develop macrophages with pro-regenerative properties for superior patient outcomes. Resolution’s initial focus is on developing RTX001, its lead product with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, to treat patients with end-stage liver disease. The Company is also advancing efforts to expand the potential of its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes’s lab at the University of Edinburgh, is based in Edinburgh and London. Learn more by visiting https://resolution-tx.com/ and engage with us on LinkedIn.

    About AASLD

    AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. It fosters research that leads to improved treatment options for millions of liver disease patients. It advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.

    SOURCE Resolution Therapeutics

    Continue Reading

  • Baker McKenzie Wong & Leow Advises on USD 1 billion Sustainability-Linked Syndicated Term Loan Facility for Aster | Newsroom

    Baker McKenzie Wong & Leow Advises on USD 1 billion Sustainability-Linked Syndicated Term Loan Facility for Aster | Newsroom

    Baker McKenzie Wong & Leow, the Singapore member firm of Baker McKenzie, has advised DBS Bank Ltd. (DBS) and OCBC Bank as mandated lead arrangers, underwriters and bookrunners for a USD 1 billion sustainability-linked syndicated loan (SLL) facility for Aster Chemicals & Energy Pte. Ltd. (Aster).

    The facility, which closed on 15 September 2025, reflected robust demand from leading banks across Singapore, Indonesia, Thailand, the UAE, Japan, and Sri Lanka. DBS and OCBC also acted as Sustainability Coordinators, ensuring alignment of the facility with Aster Group’s Environmental, Social, and Governance (ESG) objectives. The SLL is directly linked to measurable reductions in Greenhouse Gas (GHG) emissions intensity.

    Proceeds from the facility will support Aster’s general corporate purposes, including rejuvenation projects for its assets on Pulau Bukom and Jurong Island.

    The Baker McKenzie Wong & Leow team was led by Banking & Finance Principal Emmanuel Hadjidakis, supported by Local Principal Dawn Ho and Associate Qingxun Lin.

    This transaction adds to Baker McKenzie’s growing portfolio of high-profile syndicated loan deals in the region, including the USD 4.2 billion loan for Gulf Energy Development Public Company Limited and Intouch Holdings Public Company Limited and a syndicate of eight foreign lenders as well as the USD 4.5 billion SLL facility for Syngenta Group (HK) Holdings Co. Ltd.

    Baker McKenzie was recognized as the “Syndicated Corporate Loan Law Firm of the Year” at this year’s Asia Pacific Loan Market Association’s (APLMA’s) Asia Pacific Syndicated Loan Market Awards.

    Baker McKenzie Wong & Leow advised DBS Bank Ltd. and OCBC Bank as mandated lead arrangers, underwriters and bookrunners for a USD 1 billion sustainability-linked syndicated loan facility for Aster Chemicals & Energy Pte. Ltd. 

    Continue Reading

  • HIV Diagnoses Fall but Inequalities Persist, Data Show – Medscape

    1. HIV Diagnoses Fall but Inequalities Persist, Data Show  Medscape
    2. HIV testing, PrEP, new HIV diagnoses and care outcomes for people accessing HIV services: 2025 report  GOV.UK
    3. New HIV diagnoses fall in 2024, but fewer young people getting tested:…

    Continue Reading

  • Familial Cluster of Foodborne Botulism Associated with Homemade Dairy

    Familial Cluster of Foodborne Botulism Associated with Homemade Dairy

    Introduction

    Foodborne botulism is a serious form of food poisoning caused by ingestion of food contaminated with a neurotoxin produced by Clostridium botulinum.1 Ingesting as little as 30 nanograms of this toxin can result in severe…

    Continue Reading

  • Best Buy’s weeklong Techtober Sale is competing with October Prime Day

    Best Buy’s weeklong Techtober Sale is competing with October Prime Day

    Table of Contents

    Continue Reading

  • Amazon October Prime Day Pokémon deals: TCG, Loungefly, more still on sale

    Amazon October Prime Day Pokémon deals: TCG, Loungefly, more still on sale

    Ben Williams is a freelance writer at Mashable, having joined the team in June 2025. With over 10 years experience in gaming, tech, TV, anime, and film, there’s nothing he hasn’t covered. Alongside Ben’s other work at IGN,…

    Continue Reading